Ivuxolimab

DB16208InvestigationalProtein Based Therapies

Ivuxolimab is under investigation in clinical trial NCT02554812 (A Study of Avelumab in Combination With Other Cancer Immunotherapies in Advanced Malignancies (JAVELIN Medley)).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 4
Curator reviewed
Also known as: Anti-OX40 Antibody PF-04518600
Code names: PF-04518600 · PF-8600

Resolves to

Compound

UNIIAPS3IS9D6WCAS2128729-41-7

Targets

P43489TNFRSF4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ivuxolimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account